Abstract: Endometrial stromal sarcomas (ESS) are rare and understudied gynecologic mesenchymal neoplasms. These tumors can be confused with many other gynecologic and nongynecologic tumors due to their variegated morphologic appearance and nonspecific immunohistochemical profile. ESS can express cytokeratin (CK) and, therefore, may be misdiagnosed as carcinoma especially in extrauterine locations and when recurrence/metastasis is present. In this study, we investigated the expression of a wide spectrum of CKs consisting of AE1/3, CAM 5.2, HMCK, MNF116, CK5, CK6, CK7, CK8/18, CK14, CK17, CK19, and CK20 in 6 lowgrade and 5 high-grade ESS. In addition, staining for estrogen receptor, progesterone receptor, CD10, and cyclin D1 was performed. Our results showed that CKs AE1/3, CAM 5.2, MNF116, and CK8/18 are more expressed in low-grade ESS, whereas highgrade ESS express more AE1/3 and CAM 5.2. In problematic cases, especially in recurrences or metastases, the immunohistochemical panel of antibodies AE1/3, MNF116, CAM 5.2, and CK8/18, together with other classic immunohistochemical markers CD10, cyclin D1, estrogen receptor, and progesterone receptor, may be helpful in the differential diagnosis between ESS and other gynecologic and nongynecologic malignancies.
portance because it can protect patients with low-grade ESS against overtreatment with radiotherapy and inappropriate, potentially dangerous systemic chemotherapy.
The latest World Health Organization classification divides ESS into low-grade (LG), high-grade (HG), and undifferentiated uterine sarcoma (UUS) subtypes. 3 Morphologically LG ESS consists of cells, which resemble those of the normal proliferative phase of endometrial stroma. HG ESSs are neoplasms consisting of atypical cells reminiscent of endometrial stromal cells, but lacking the degree of pleomorphism necessary for a diagnosis of UUS. 1 The expression of some subtypes of cytokeratins (CKs) in ESS has been reported. 4, 5 However, only one study investigated the expression of a relatively wide spectrum of CKs in ESS. 6 The aim of this study was to analyze the expression of a broad spectrum of common CKs antibodies in a series of LG and HG ESS in order to evaluate whether these express the same subtypes of CKs. The relationship of CKs expression with CD10, estrogen receptor (ER), progesterone receptor (PR), and cyclin D1 was also investigated.
METHODS
The pathology database of a general community hospital were searched for all cases of uterine LG and HG ESS between 2010 and 2013 and 11 cases were retrieved.
All cases arose in corpus uteri. Haematoxylin and eosin stained slides were concomitantly reviewed by 2 authors (S.R. and C.M.). The cases were classified as LG and HG according to 2014 World Health Organization classification. Histologic features for differentiating LG from HG neoplasms were a grade of nuclear atypia, necrosis and pattern of myometrial invasion. Both LG and HG lesions showed resemblance to the proliferative phase of endometrial stroma.
On the basis of morphology and immunohistochemistry LG ESS were differentiated from HG ESS, gland-poor adenomyosis, cellular leiomyoma, intravascular leiomyomatosis, leiomyosarcoma with extensive intravascular component, uterine tumors resembling ovarian sex cord tumor, adenosarcoma, and perivascular epithelioid cell tumor.
HG ESS were distinguished from LG ESS, carcinosarcoma, leiomyosarcoma, and UUS. No case showed a biphasic pattern of growth.
Uterine tumors resembling ovarian sex cord tumor were not included in this study.
Clinical data were reviewed from all patients and consisted of age, surgical treatment, and adjuvant therapies. The stage at disease presentation was determined according to FIGO and by reviewing pathology reports of a primary tumor. The pathologic stage was reported for all patients.
The study was approved by the Proportionate Review Sub-Committee of the Wales REC 6 (REC reference 16/WA/0079).
IMMUNOHISTOCHEMISTRY
Serial sections at 3.5 μm were cut from formalinfixed paraffin-embedded tissue blocks, mounted onto adhesive slides (Surgipath Snowcoat) and dried at 65°C for 15 minutes. Each series of sections were stained on Bond III Automated Immunohistochemistry System Leica Stainer using Leica Bond Polymer Refine detection with a 3,3'-diaminobenzidine chromogen (0.5% copper sulfate in phosphate-buffered saline buffer). All antigen retrieval methods were performed on-board, following Queen Alexandra Hospital laboratory protocols, using antigenunmasking solutions: epitope retrieval solution 1 (ER1) at pH 6.0 (Leica, AR9961) and epitope retrieval solution 2 (ER2) at pH 9.0 (Leica, AR9640) for 20 minutes. Each run included a positive control (normal endometrium) and a negative control where the primary antibody was omitted.
CK markers tested were, as follows: AE1/3, CAM 5.2, HMWCK, MNF116, CK5, CK6, CK7, CK8/18, CK14, CK17, CK19, and CK20. In addition, staining for ER, PR, CD10, and cyclin D1 was performed. Details of antibodies (sources, clones, working dilutions and antigen retrieval pretreatment) are summarized in Table 1 .
The staining was assessed with a semiquantitative method as shown in Table 2 .
RESULTS
The mean age of patients in both groups was 63 years (median, 62 y; range, 35 y). Six patients had LG ESS (Fig. 1A , case 3) and 5 patients had HG ESS (Fig. 1B , case 11). Two patients with LG ESS were FIGO STAGE IA, 1 was stage IB, 1 was stage IIB, 1 was IIIA, and 1 patient showed pelvic recurrence, after 49 years, of uterine "malignant haemangiopericytoma."
One patient with HG ESS was FIGO stage IA, 1 was stage IB, 1 was IIIB, and 2 were stage IVA.
The clinicopathologic data are summarized in Table 3 .
Immunohistochemistry

CKs Expression in LG ESS
All cases except 1 (case 4) were positive with AE1/3 ( Fig. 2A) and CAM 5.2. Four cases (cases 1, 2, 5, and 6) were positive with MNF116 ( Fig. 2B ) and 2 cases (cases 3 and 4) were negative.
All cases except 1 (case 1) were negative with CK6. Three cases (cases 1, 5, and 6) were positive with CK8/18 ( Fig. 2C ) and 3 cases (cases 2, 3, and 4) were negative. 
CKs Expression in HG ESS
Three cases (cases 7, 9, and 11) were positive with AE1/3 and 2 cases (cases 8 and 10) were negative. All cases except 1 (case 10) were positive with CAM 5.2 (Fig. 3) .
All cases except 1 (case 11) were negative with MNF116 and all cases except 1 (case 9) were negative with CK6 and CK8/18.
All LG and HG ESSs were negative with CKs 5, 7, 14, 17, 19, 20, and HMWCK.
In all cases of LG and HG ESSs, the staining of CKs was cytoplasmic. The extension and intensity were different among cases.
CD10 was positive in all LG and HG ESSs. Nevertheless, not all cases showed diffuse staining.
All LG ESSs demonstrated positive immunostaining with ER and PR except case 4 which was negative for ER. Interestingly this case showed also negative staining with all CKs.
Three HG ESSs (cases 7, 9, and 10) were negative with ER and PR, whereas 2 HG ESSs (cases 8 and 11) were positive.
Cyclin D1 was positive in all HG ESSs and negative in all LG ESSs.
No relationship was found between the expression of CKs and ER, PR, and cyclin D1.
The results of immunohistochemical findings are shown in Table 4 .
DISCUSSION
In this study, we showed that, among the broad spectrum of CKs, the most diagnostically useful for both LG and HG ESS were AE1/3, MNF116, CAM 5.2, and CK8/18. There was no significant difference between LG and HG ESS in terms of expression of CKs subtypes.
Immunohistochemically, CD10 is routinely used for diagnosis of endometrial stromal tumors, but it is well known that this antibody is not specific for the diagnosis of ESS. 7, 8 Furthermore, some ESS may also show no immunoreactivity with CD10. 9 Although the histologic diagnosis of the classic type of LG ESS is usually simple and straightforward, problematic cases also exist. Some ESS may show epithelioid morphology 10 with the presence of glands, pseudopapillae 11 , and cord-like structures. 12 LG ESS may present different genetic rearrangementssuch as JAZF1-SUZ12, JAZF1-PHF1, EPC1-PHF1, MEAF6-PHF1, ZC3H7B-BCOR, and MBTD1-CXorf67 13-15 but a subgroup of LG ESS, with classic morphology and immunoprofile, shows no known and definite genetic aberration. 16 In contrast to LG ESS, the diagnosis of HG ESS is more challenging. Some HG ESS can show intratumoral morphologic variability with areas of LG ESS which, contrary to HG ESS, can show positive immunostaining for ER and negative staining for cyclin D1. None of the cases of HG ESS reported herein showed convincing evidence of the presence of LG ESS.
The relatively recent recognition of a subgroup of ESS with YWHAE-NUTM2 gene rearrangement and complex morphology supports the existence of a category of ESS which is morphologically HG and seems to have an intermediate prognosis between LG ESS and UUS. 17 It is worth mentioning that none of the HG ESS in this study showed the morphology of YWHAE-NUTM2 positive HG ESS such as the presence of round cells arranged in nests with a delicate stromal capillary network and cytologically bland and mitotically active spindle cell component with a fibrous/fibromyxoidstroma. In surgical resection specimens, when a sufficient amount of tissue is available for histologic analysis, the differential diagnosis between ESS and leiomyoma (cellular variant), leiomyosarcoma, adenocarcinoma with spindle cell morphology, and endometrioid adenocarcinoma arising in atypical polypoid adenomyoma should usually not be problematic. One should bear in mind that some morphologic features of spindle cell endometrioid adenocarcinoma such as corded and hyalinised areas can also be present in ESS. In the above mentioned malignancies, for the differential diagnosis with ESS, immunohistochemical analysis of CKs would not be as useful as morphologic characteristics and possible molecular investigation findings. The classic vascular architecture and the pattern of invasion of ESS are important clues for making correct diagnosis.
In bioptic tissue when the classic morphology of ESS such as typical vascular architecture and the pattern of invasion is not present, diagnosis could be difficult. The diagnosis of metastatic or recurrent ESS is even more complex, because of the occurrence of different morphology from an original tumor. 18 In addition, due to its nonspecificity, positive immunostaining for CD10 is not entirely reliable. In these cases the immunohistochemical panel of CKs AE1/3, MNF116, CAM 5.2, CK8-18 could be useful for rendering correct diagnosis of ESS.
The molecular investigation is an expensive and time-consuming method, however, when suitable, should be performed. The data from the literature show that not all cases of ESS (LG and HG) harbor genetic fusion.
Our findings partly confirm the previous results by Adegboyega et al. 6 However, none of our cases expressed CK19. This may be due to the different clone of an antibody or technical process used in the study of Adegboyega and colleagues.
ESS is a very rare neoplasm, and although, theoretically, 11 cases could represent a reasonable number, the findings reported herein are still insufficient for definite conclusions and other studies with a large number of cases are warranted to confirm our data. LG ESS  1  2+3  2+2  1+2  1+1  1+2  +D  +  +  0  2  1+2  1+2  1+2  0  0  +F  +  +  0  3  2+3  1+2  0  0  0  +D  +  +  0  4  0  0  0  0  0  +D  0  +  0  5  4+3  4+3  4+3  0  3+3  +D  +  +  0  6  3+3  3+3  2+3  0  3+3  +D  +  +  0  HG ESS  7  1+3  1+2  0 LG, low grade; PR, progesterone receptor.
